Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02044380 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Afatinib

Sponsor

Boehringer Ingelheim